A shorter course of radiation with three drugs for newly diagnosed lymphoma that starts in the brain or spinal cord
Official title: Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether a short radiation course plus three drugs can help people just diagnosed with a lymphoma that starts in the brain or spinal cord.
Read our full plain-language summary
What the trial team says
This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma.
Key facts
- Registry number
- NCT07749365
- Stage of testing
- Phase 2
- Conditions studied
- DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
Where it is running
This trial lists 1 site.
-
Fujian
- The First Affiliated Hospital of Xiamen University (Xiamen)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.